프론트바이오 - 로고

History

  • About FRONTBIO
  • History
  • 2010 - 2013

    Incorporated, and Growth
    Scaffold Established

  • 2014 - 2017

    Foundation of
    R&D Established

  • 2018 - 2021

    Growth Momentum
    Secured

  • 2013.05

    Entered into a Technology Transfer Agreement with YD Global Life Science of Agent Treating Chemotherapy Induced Peripheral Neuropathy

  • 2013.02

    Entered into a Technology License Agreement with S&D CO., Ltd of Material for Controlling Blood Glucose Following Food Consumption

  • 2011.01

    Obtained Certification of Venture Company By KIBO (R&D Company)

  • 2010.03

    FRONTBIO Inc. Incorporated.

  • 2017.10

    Obtained Patent Registration of Composition for Prevention or Treatment of Diabetes Complication, and the Patent Transferred to Hallym University

  • 2017.05

    Obtained Registration of Patent of Composition for Prevention or Treatment of Diabetes Complication, and the Patent Transferred to Hallym University

  • 2016.11

    Entered into a Patent License Agreement with Hallym University of Composition for Inhibiting Diabetic Renal Fibrosis Comprising FB700

  • 2016.05

    Changed the Address of Head office to 32, Soyanggang-ro, Chuncheon-si, Gangwon-do

  • 2016.04

    Obtained Certification of R&D Center By KOITA

  • 2014.03

    Obtained Registration of Patent of Composition for Prevention or Treatment of Diabetes Complication Comprising Decaffeoyl Quinic Acid Derivatives

  • 2021.01

    Changed the Address of Head office to #301~302, Bio.#2, 32 Soyanggang-ro, Chuncheon-si, Gangwon-do

  • 2021.01

    Eczema therapeutics(FB700) clinical phase1 IND approval

  • 2020.07

    Performed FB300 Nonclinical Study

  • 2020.01

    Applied for Patent Registration of Pharmaceutical Composition for Preventing or Treating Cancer Comprising Complex of FB300-A and FB301-B Derivatives as Active Ingredients

  • 2019.12

    Opened Seoul Branch Office with the address of Samseong-dong , Gangnam-gu, Seoul

  • 2019.05

    Obtained Registration of Patent of Pharmaceutical Composition for Preventing or Treating Cancer Comprising FB300-A and FB302-B.

  • 2018.10

    Obtained Registration of Patent Pharmaceutical Composition for Preventing or Treating Diabetic Neuropathic Pain Comprising FB100 or its Pharmaceutically Acceptable Salts as Active Ingredients, and the Patent Transferred to Hallym University

  • 2018.03

    Obtained Patent Registration of Pharmaceutical Composition for Preventing or Treating Skin Disease Comprising FB700